High Court to Review Myriad (MYGN) Patent on Genes

November 30, 2012 3:50 PM EST Send to a Friend
Shares of generic drug maker Myriad Genetics Inc. (Nasdaq: MYGN) experienced volatility on Friday when news broke that the U.S. high court was going decide whether human genes can be patented.

Myriad Genetics holds patents on two genes linked to hereditary breast and ovarian cancer.

In August the U.S. Federal Circuit Court of Appeals upheld the biotechnology company's right to patent specific genes that account for inherited forms of the two cancers.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Litigation

Add Your Comment